Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK.

J Clin Oncol. 2011 Jun 1;29(16):2171-7. doi: 10.1200/JCO.2010.32.3139. Epub 2011 Apr 18.

2.

Functional outcome 5 years after non-operative treatment of type A spinal fractures.

Post RB, Keizer HJ, Leferink VJ, van der Sluis CK.

Eur Spine J. 2006 Apr;15(4):472-8. Epub 2005 Jun 4.

3.

Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands.

ten Bokkel Huinink WW, van Groeningen CJ, Voest EE, Peters WG, Keizer HJ, de Witte JH.

Neth J Med. 2003 Jul;61(7):249-56.

4.

Functional outcome in patients with thoracolumbar burst fractures treated with dorsal instrumentation and transpedicular cancellous bone grafting.

Leferink VJ, Keizer HJ, Oosterhuis JK, van der Sluis CK, ten Duis HJ.

Eur Spine J. 2003 Jun;12(3):261-7. Epub 2003 Mar 21.

5.

External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients.

Vergouwe Y, Steyerberg EW, de Wit R, Roberts JT, Keizer HJ, Collette L, Stenning SP, Habbema JD.

Br J Cancer. 2003 Mar 24;88(6):843-7.

6.

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

Svancárová L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, Keizer HJ, Hermans C, van Glabbeke M, Verweij J, Hogendoorn PC, Nielsen OS.

Eur J Cancer. 2002 Mar;38(4):556-9.

PMID:
11872349
7.

Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.

Punt CJ, Keizer HJ, Douma J, Skovsgaard T, Schüller J, Muller EW, Ten Napel CH, Croles JJ, Lochs H, Zhang J, Hammershaimb L.

Ann Oncol. 2002 Jan;13(1):81-6.

PMID:
11865814
8.

Residual mass histology in testicular cancer: development and validation of a clinical prediction rule.

Steyerberg EW, Vergouwe Y, Keizer HJ, Habbema JD; ReHiT Study Group.

Stat Med. 2001 Dec 30;20(24):3847-59.

PMID:
11782038
9.

Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited.

Tamsma JT, Keizer HJ, Meinders AE.

Ann Oncol. 2001 Oct;12(10):1353-7. Review.

PMID:
11762804
10.

Distribution of ifosfamide and metabolites between plasma and erythrocytes.

Kerbusch T, Herben VM, Jeuken MJ, Ouwerkerk J, Keizer HJ, Beijnen JH.

Biopharm Drug Dispos. 2001 Apr;22(3):99-108.

PMID:
11745912
11.

Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.

Kerbusch T, Mathĵt RA, Keizer HJ, Ouwerkerk J, Rodenhuis S, Schellens JH, Beijnen JH.

Eur J Clin Pharmacol. 2001 Sep;57(6-7):467-77.

PMID:
11699611
12.

Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.

Kerbusch T, Mathôt RA, Keizer HJ, Kaijser GP, Schellens JH, Beijnen JH.

Drug Metab Dispos. 2001 Jul;29(7):967-75.

13.
14.

Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Kerbusch T, de Kraker J, Keizer HJ, van Putten JW, Groen HJ, Jansen RL, Schellens JH, Beijnen JH.

Clin Pharmacokinet. 2001 Jan;40(1):41-62. Review.

PMID:
11236809
15.

Diabetes insipidus in metastatic cancer: two case reports with review of the literature.

Huinink DT, Veltman GA, Huizinga TW, Roelfsema F, Keizer HJ.

Ann Oncol. 2000 Jul;11(7):891-5. Review. No abstract available.

PMID:
10997822
17.

Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

Kerbusch T, Huitema AD, Ouwerkerk J, Keizer HJ, Mathôt RA, Schellens JH, Beijnen JH.

Br J Clin Pharmacol. 2000 Jun;49(6):555-61.

18.

Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature.

Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, Cleton FJ, Osanto S.

J Clin Oncol. 2000 May;18(10):2169-78. Review.

PMID:
10811682
19.

Retroperitoneal metastases in testicular cancer: role of CT measurements of residual masses in decision making for resection after chemotherapy.

Steyerberg EW, Keizer HJ, Sleijfer DT, Fossâ SD, Bajorin DF, Gerl A, de Wit R, Kirkels WJ, Koops HS, Habbema JD.

Radiology. 2000 May;215(2):437-44.

PMID:
10796922
20.

Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.

Vahrmeijer AL, van Dierendonck JH, Keizer HJ, Beijnen JH, Tollenaar RA, Pijl ME, Marinelli A, Kuppen PJ, van Bockel JH, Mulder GJ, van de Velde CJ.

Br J Cancer. 2000 May;82(9):1539-46.

Supplemental Content

Loading ...
Support Center